Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase II Trial of a New Customized Dosing (RADAR Dosing) of Niraparib As Maintenance Therapy in Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Recurrent Cancer Patients

NCT03891576 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT03891576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03891576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase II Trial of a New Customized Dosing (RADAR Dosing) of Niraparib As Maintenance Therapy in Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Recurrent Cancer Patients
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Phase 2
Overall status
Terminated
Start date
November 13, 2019
Completion date
August 31, 2024
Enrollment
83 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma